<!DOCTYPE html>
<html>
<head lang="en">
	<meta charset="UTF-8">
	<meta name="viewport" content="width=device-width,initial-scale=1, maximum-scale=1, minimum-scale=1, user-scalable=no">
	<link rel="icon" href="img/logo.ico" type="image/x-icon"/>
	<title>硅康医药-硅康技术</title>
	<meta name="Keywords" content="" />
	<meta name="Description" content="用最精准的计算方法突破传统研发瓶颈,为人类的重大疾病寻找新一代创新药物" />
	<link rel="icon" href="img/logo.ico" type="image/x-icon"/>
	<link rel="stylesheet" href="//cdn.bootcss.com/normalize/4.2.0/normalize.min.css">
	<link rel="stylesheet" href="css/common.css">
	<script type="text/javascript" src="//cdn.bootcss.com/jquery/2.1.1/jquery.min.js"></script>
	<script type="text/javascript" src='http://res.wx.qq.com/open/js/jweixin-1.2.0.js'></script>
</head>
<body>
	<img src="img/share_logo.png" style='width:0;height:0;overflow:hidden;float:left;'>
	<div class='menu'>
		<div class='tab clearfix'>
			<ul class='clearfix'>
				<li>
					<a href="index.html">关于硅康</a>
				</li>
				<li class='active'>
					<a href="science.html">硅康技术</a>
				</li>
				<li>
					<a href="team.html">硅康团队</a>
				</li>
				<li>
					<a href="news.html">硅康新闻</a>
				</li>
			</ul>
			<p>
				<a href="http://www.silicontx.com/">
					<span class='active'>中</span>/<span>En</span>
				</a>					
			</p>
		</div>
		<div class='del'>
			<i class="iconfont">&#xe61c;</i>
		</div>
	</div>
	<div class='wrap'>
		<header>
			<div class='layout clearfix'>
				<div class='logo'>
					<a href="index.html">
						<img src="img/logo.png">
					</a>
				</div>
				<div class='tab clearfix'>
					<ul class='clearfix'>
						<li>
							<a href="index.html">关于硅康</a>
						</li>
						<li class='active'>
							<a href="science.html">硅康技术</a>
						</li>
						<li>
							<a href="team.html">硅康团队</a>
						</li>
						<li>
							<a href="news.html">硅康新闻</a>
						</li>
					</ul>
					<p>
						<a href="http://www.silicontx.com/">
							<span class='active'>中</span>/<span>En</span>
						</a>					
					</p>
				</div>
				<div class='tab_icon'>
					<img src="img/tab.png">
				</div>
			</div>
		</header>
		<div class='science_banner'>
			<div class='science_intro layout'>
				<div class='intro'>
					“……生命体所做的一切行为都可以理解为原子间有规律的，或温和或剧烈的跃动。”
				</div>
				<div class='line'></div>
			</div>
			<div class='intro_img'>
				<img src="img/science_banner.png">
			</div>
		</div>
		<div class='science_cards'>
			<div class='cards_list layout'>
				<div class='science1 card'>
					<div>
						<img src="img/science1.png">
					</div>					
					<p>通过长时间的大规模模拟，现如今我们可以看到小分子通过结合来改变蛋白质构象的整个流程</p>
				</div>
				<div class='science2 card'>
					<div>
						<img src="img/science2.png">
					</div>					
					<p>前所未有的计算能力造就了新一批工具：单就GPU而言，它已经拥有100倍的速度提升(FGPA与ASIC也能让处理能力提高多个数量级)</p>
				</div>
				<div class='science3 card'>
					<div>
						<img src="img/science3.png">
					</div>					
					<p>通过详尽的量子力学方法，我们有能力为亚原子粒子建模，从而进一步精准地模拟金属粒子相互作用</p>
				</div>
			</div>
		</div>
		<div class='science_detail'>
			<div class='intro layout'>
				<p>
					<span>硅康医药是一家集成计算医药研发公司，</span>
					采用严密的、基于物理的大规模模拟来极大地加快药物研发过程。公司的发展以结合了量子力学和分子动力学两者优势的核心平台为基础。目前，我们正在部署海量计算资源，包括内部集群和云计算，以研发与多种人类疾病有密切关联、而在此前一直被视为“无法合成”的靶向药物。
				</p>
				
				<p>
					从而比传统实验方法更加快速且高效地进行计算机化的亲和度与选择度分析。我们将模拟、实验结合体与测定物紧密结合，从而可以缩短设计周期，并且提高理想化合物的数量。基于此，硅康医药不仅在精准度上具有显著优势，能够攻克极其复杂的生物化学难题，而且在速度上也有质的飞跃。
				</p>
				<p>
					<span>硅康医药创建的前提基础是</span>
					——最终，“……一切生命体都可以从原子间有规律的、或温和或剧烈的跃动层面来理解。”（理查德‧费曼）。虽然我们距离高效模拟细胞、器官和有机体方面还有很长的路要走，但是通过当前最尖端的科学方法，我们能够精准地模拟蛋白质间及蛋白质与配体的结合。我们的系统采用显式水分子进行全原子分子动力学模拟，并准确进行分子建模，能够预测与目的靶标和非靶标有关的结合能，
				</p>
				<p>
					<span>我们的科学领导团队</span>
					已经在与上述话题有关的计算机辅助药物设计领域发表了多篇开创性的论文，重点关注如何运用严密的全原子模拟来计算分子结合亲和度、选择度、热力学和虚拟药物筛选。您可以从下列已发表论文了解我们所做的工作与采用的方法。
				</p>
			</div>
		</div>
		<div class='science_article'>
			<div class='layout'>
				<div class='title'>
					<h1>科研论文</h1>
					<div class='line'></div>
				</div>
				<div class='article'>
					<div class='article_left'>
						<div class='left1'>
							<h3>Binding Affinity</h3>

							<p class='msg'>Accurate and reliable prediction of relative ligand binding potency in prospective drug discovery by way of a modern free-energy calculation protocol and force field</p>
							<p class='time'>--L Wang et al., J. Am.<br>
							Chem. Soc., 137 (7), 2695-2703, 2015</p>
						
							<p class='msg'>Accurate binding free energy predictions in fragment optimization</p>
							<p class='time'>--TB Steinbrecher, et al., J. <br>
							Chem. Inf. Model., 55 (11), 2411-2420, 2015</p>

							<p class='msg'>Predicting binding affinities for GPCR ligands using free-energy perturbation</p>
							<p class='time'>--EB Lenselink, et al.,<br>
							ACS Omega, 1 (2), 293-304, 2016</p>

							<p class='msg'>Relative Binding Free Energy Calculations Applied to Protein Homology Models</p>
							<p class='time'>--D Cappel, ML Hall, EB Lenselink, T Beuming, J Qi, J Bradner, W Sherman<br>
							J. Chem. Inf. Model., 56 (12), 2388-2400, 2016</p>
							
						</div>
						<div class='left2'>
							<h3>Water Thermodynamics</h3>

							<p class='msg'>Differential water thermodynamics determine PI3K-Beta/Delta selectivity for solvent-exposed ligand modifications</p>
							<p class='time'>--D Robinson, et al.,<br>
							J. Chem. Inf. Model., 56 (5), 886-894, 2016 </p>

							<p class='msg'>Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase</p>
							<p class='time'>--PW Snyder, et al., <br>
							Proc. Nat. Acad. Sci., 108 (44), 17889-17894, 2011</p>

							<p class='msg'>Water networks contribute to enthalpy/entropy compensation in protein–ligand binding</p>
							<p class='time'>--B Breiten, et al.<br>
							J. Am. Chem. Soc., 135 (41), 15579-15584, 2013</p>

							<p class='msg'>Interactions between Hofmeister anions and the binding pocket of a protein</p>
							<p class='time'>--JM Fox, et al.,<br>
							J. Am. Chem. Soc., 137 (11), 3859-3866 2015</p>

							<p class='msg'>Thermodynamic analysis of water molecules at the surface of proteins and applications to binding site prediction and characterization</p>
							<p class='time'>--T Beuming, Y Che, R Abel, B Kim, V Shanmugasundaram, W Sherman,<br>
							Prot. Struct. Funct, Bioinf., 80 (3), 871-883, 2012</p>

							<p class='msg'>High-energy water sites determine peptide binding affinity and specificity of PDZ domains</p>
							<p class='time'>--T Beuming, R Farid, W Sherman,<br>
							Prot. Sci., 18 (8), 1609-1619, 2009</p>

							<p class='msg'>Hydration site thermodynamics explain SARs for triazolylpurines analogues binding to the A2A receptor</p>
							<p class='time'>--C Higgs, T Beuming, W Sherman,<br>
							ACS Med. Chem. Lett., 1 (4), 160-164, 2010</p>
						</div>
					</div>
					<div class='article_center'></div>
					<div class='article_right'>
						<div class='right1'>
							<h3>Binding Selectivity</h3>

							<p class='msg'>Novel method for probing the specificity binding profile of ligands: applications to HIV protease</p>
							<p class='time'>-- W Sherman, B Tidor,<br>
							Chem. Bio. Drug Des., 71 (5), 387-407, 2006</p>
						
							<p class='msg'>Rational approaches to improving selectivity in drug design</p>
							<p class='time'>--DJ Huggins, W Sherman, B Tidor,<br>
							J. Med. Chem., 55 (4), 1424-1444, 2012</p>

							<p class='msg'>Understanding kinase selectivity through energetic analysis of binding site waters</p>
							<p class='time'>--DD Robinson, W Sherman, R Farid,<br>
							ChemMedChem, 5 (4), 618-627, 2010</p>

						</div>
						<div class='right2'>
							<h3>Solvation Free Energy Calculations</h3>

							<p class='msg'>Prediction of absolute solvation free energies using molecular dynamics free energy perturbation and the OPLS force field</p>
							<p class='time'>--D Shivakumar, J Williams, Y Wu, W Damm, J Shelley, W Sherman,<br>
							J. Chem. Theory Comput., 6 (5), 1509-1519, 2010</p>

							<p class='msg'>Improving the prediction of absolute solvation free energies using the next generation OPLS force field</p>
							<p class='time'>--D Shivakumar, E Harder, W Damm, RA Friesner, W Sherman,<br>
							J. Chem. Theory Comput., 8 (8), 2553-2558, 2012</p>
						</div>
						<div class='right3'>
							<h3>Virtual Screening and Drug Design</h3>

							<p class='msg'>Generation of receptor structural ensembles for virtual screening using binding site shape analysis and clustering</p>
							<p class='time'>--DJ Osguthorpe, W Sherman, AT Hagler,<br>
							Chem. Bio. Drug Des., 80 (2), 182-193, 2012</p>

							<p class='msg'>Exploring protein flexibility: incorporating structural ensembles from crystal structures and simulation into virtual screening protocols</p>
							<p class='time'>--DJ Osguthorpe, W Sherman, AT Hagler,<br>
							J. Phys. Chem. B, 116 (23), 6952-6959, 2012</p>

							<p class='msg'>Boosting virtual screening enrichments with data fusion: coalescing hits from two-dimensional fingerprints, shape, and docking</p>
							<p class='time'>--GM Sastry, VSS Inakollu, W Sherman,<br>
							J. Chem. Inf. Model., 53 (7), 1531-1542, 2013</p>

							<p class='msg'>Selecting an optimal number of binding site waters to improve virtual screening enrichments against the adenosine A2A receptor</p>
							<p class='time'>--EB Lenselink, T Beuming, W Sherman, HWT van Vlijmen, AP IJzerman,<br>
							J. Chem. Inf. Model., 54 (6), 1737-1746, 2014</p>

							<p class='msg'>Discovery of furan carboxylate derivatives as novel inhibitors of ATP-citrate lyase via virtual high-throughput screening.</p>
							<p class='time'>--Jernigan FE, Hanai J, Sukhatme VP, Sun L, Bioorg. Med. Chem. Lett. <br>
							27 (4), 929-935, 2017</p>

							<p class='msg'>Design and synthesis of emodin derivatives as novel inhibitors of ATP-citrate lyase. </p>
							<p class='time'>--Koerner SK, Hanai J, Bai S, Jernigan FE, Oki M, Komaba C, Shuto E,  <br>
							Sukhatme VP, Sun L, Eur. J. Med. Chem. 126, 920-928, 2017</p>

							<p class='msg'>Glycopeptide analogues of PSGL-1 inhibit P-selectin in vitro and in vivo. </p>
							<p class='time'>---Krishnamurthy VR, et al. Nat. Commun. 6, 6387, 2015</p>

							<p class='msg'>Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. </p>
							<p class='time'>--Ying W, et al. Mol. Cancer Ther. 11, 475, 2012.</p>
						</div>
					</div>
				</div>
				<div class='icon'>
					<img src="img/science4.png">
				</div>
			</div>
		</div>
		<footer>
			<div class='layout'>
				<img src="img/logo_footer.png">
				<span>&copy;2016&nbsp;硅康医药&nbsp;
				<a href="http://www.miitbeian.gov.cn/" target='_blank'>京ICP备17031150号-1</a></span>
			</div>
		</footer>
	</div>
	
	<script type="text/javascript" src='js/common.js'></script>
</body>
</html>